Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

Overview of attention for article published in Gastroenterology, December 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source
twitter: 12 X users

facebook: 1 Facebook page
reddit: 2 Redditors
guideline: 5 clinical guideline sources

Readers on

mendeley: 152 Mendeley

So far, Altmetric has seen 13 X posts from 12 X users, with an upper bound of 64,342 followers.

Adalimumab and immunomodulator use and lymphoma risk data here: http://t.co/Qlb3mqWcUt #PIBD

An interesting study observing the possible risks of anti-TNF combo vs.monotherapy in #Crohns #IBD http://t.co/pYU4dzrj8h

Beware of the Swinging Pendulum: Anti-TNF combination therapy increases the risk of malignancy. http://t.co/pYU4dzrj8h

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 9 additional X posts.